concern quarter slightli revis estim
water report somewhat mix second-quart result back difficult first
quarter although given concern around food safeti growth china market share
loss mass spec/lc come quarter expect constant-curr growth
better expect sum strong growth recur revenu ta busi line
china particularli pharma somewhat off-set slower growth academic/
industri india weaker instrument sale compani continu
see weak high-resolut mass spec sale biomed custom delay
capital-expenditure spend larg pharma foreign currenc translat ad growth
slightli target adjust ep beat target
consensu primarili driven better margin
term guidanc manag maintain full year revenu growth guidanc
constant currenc lower expect foreign-curr tailwind guidanc
midpoint earlier adjust ep expect slightli lower
previous expect versu prior mainli due
currenc impact manag expect foreign currenc impact adjust ep
neutral versu benefit earlier third quarter constant-curr revenu growth
also expect headwind currenc translat
third quarter adjust ep third quarter expect
expect third-quart revenu million ep estim
revenu billion versu prior billion full year earn per share
versu prior
call manag provid updat factor respons first-quart
weak includ under-perform mass spectrometri indian market mass
spectrometri perform improv sequenti driven strength core tandem
quad portfolio albeit off-set high-resolut mass spectrometri product line
extent salesforc realign complet perform india
remain flattish second quarter pharma growth off-set weak
industri academ govern segment howev manag highlight
pharma growth india turn posit second quarter market soft continu
eas emerg pent-up demand net/net continu see pocket
weak compani organ profil improv rel first quarter evid
continu see posit trajectori metric year view
water high-qual compani high strong cash flow gener high margin
broad exposur posit secular dynam increas pill usag global growth
regul market growth biolog histor pocket weak
good buy opportun maintain outperform rate
water corpor manufactur distribut analyt chemistri instrument focus separ
technolog liquid converg chromatographi mass spectrometri thermal analysi also provid
relat consum servic solut use pharma biotech govern industri biochem
food safeti environment custom identifi monitor measur composit materi
return equiti ttm
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
perform end-market pharma segment grew overal constant-curr basi within double-digit growth
china off-set declin develop market compani larg custom slow releas budget
manag encourag strong growth posit invest trend larg molecul busi industri
segment report constant-curr growth strength ta brand sale manag report posit perform
chemic materi market off-set weaker demand food environment custom industri end-
market strong comp china india well larg environment busi purchas order second quarter
growth academ govern end market acceler slower first quarter region contribut
perform strong trend materi clinic diagnost off-set weak bio-med
perform geographi region level asia outperform grow constant currenc report
growth china off-set flattish india perform china report strong demand pharma food materi
manag comment expect signific impact tariff point due divers product portfolio
well suppli busi set america report overal growth declin sale off-set strong
growth canada mexico puerto rico market weak bio-med research larg pharma although gener
biotechnolog encourag manag expect demand pick second half year europ report
constant-curr growth report strong trend industri academ govern end-market
pharmaceut demand slightli slower strong comp prior year
perform product line brand overal sale grew constant currenc instrument sale growth flat
quarter weak continu mass spectrometri line soft demand bio-med research challeng
high-resolut mass spectrometri product manag continu see mass spectrometri prioriti invest
keep portfolio align industri demand chromatographi product perform well continu broad-bas
demand acquiti arc system good ramp-up acquiti brand recur revenu report growth
ta product line grew constant currenc report growth across thermal analysi microcalorimetri
product line compani introduc nine new instrument ta brand discoveri seri past two
year manag note rich product pipelin highlight acquisit proslia desi technolog earlier
week desi complementari compani exist imag technolog product serv strateg product addit
portfolio water continu view acquisit opportunist tactic rather capit deploy strategi empow
softwar solut also continu competit advantag help support custom face increasingli stringent
regulatori requir complianc data manag water invest develop move toward
financi perform adjust gross margin increas basi point posit impact product mix
oper margin increas basi point foreign currenc translat particularli gbp cost base advers
impact cost water also develop comprehens program drive oper effici cost line non-
earn per share grew quarter outflow includ million toward tax reformth first
payment previous announc million tax liabil paid eight-year period water repurchas million
share quarter million consider
model chang updat model reflect report second-quart result revis guidanc closer look
guidanc indic manag appear optimist revenu growth pick third quarter
acceler fourth quarter estim full-year revenu billion versu prior billion includ
water segment revenu billion versu prior billion ta segment revenu billion unchang
rais full-year constant-curr sale forecast versu prior gross margin estim versu
prior oper margin estim versu prior essenti unchang model full-year
earn per share versu prior third quarter model revenu million ep
varianc analysi waterfal rel estim found follow page
sale
interest expens net
non recur item net tax
total revenu
million fiscal year end decemb
compani report william blair compani estim
william blair compani estimatesexhibit corporationwaterfal william blair report adjust ep ccsale fxcogssg ar dinteresttaxshareadj ep act ep us miss vs wbbeat vs william blair compani estimatesexhibit corporationwaterfal william blair previou updat adjust ep estimateswat dvsn revenue ta dvsn revenue cogssg ar dinteresttaxsharesupd estimatesep us neg impactposit william blair
compani reportsexhibit corporationconst currenc growth end marketconst currenc growth
blair compani estimatesexhibit model chang water corpor blair
million except per share data
total revenu
interest expens incom
non recur item net tax
